Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma

被引：0

作者：

Niknafs, N. ^{[1
]}

Forde, P. ^{[1
]}

Lanis, M. ^{[1
]}

Belcaid, Z. ^{[1
]}

Smith, K. ^{[1
]}

Sun, Z. ^{[2
]}

Balan, A. ^{[1
]}

White, J. ^{[1
]}

Cherry, C. ^{[1
]}

Shivakumar, A. ^{[1
]}

Shao, X. ^{[1
]}

Kindler, H. ^{[3
]}

Purcell, T. ^{[4
]}

Santana-Davila, R. ^{[5
]}

Dudek, A. ^{[6
]}

Borghaei, H. ^{[7
]}

Illei, P. ^{[1
]}

Velculescu, V. ^{[1
]}

Karchin, R. ^{[1
]}

Brahmer, J. ^{[1
]}

Ramalingam, S. ^{[8
]}

Anagnostou, V. ^{[1
]}

机构：

[1] Johns Hopkins Canc Ctr, Thorac Oncol, Baltimore, MD USA

[2] Frontier Sci Fdn, Ecog Acrin Biostat Ctr, Boston, MA USA

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA

[5] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[6] Metro Minnesota Community Oncol Res Consortium, St Luis Pk, MN USA

[7] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[8] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期

关键词：

mesothelioma; immunotherapy; multi-omics; genomics;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA12.01

引用

页码：S867 / S868

页数：2

共 50 条

[31] Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma
Metaxas, Yannis
Rivalland, Gareth
Mauti, Laetitia A.
Klingbiel, Dirk
Kao, Steven
Schmid, Sabine
Nowak, Anna K.
Gautschi, Oliver
Bartnick, Tammo
Hughes, Brett G.
Bouchaab, Hasna
Rothschild, Sacha I.
Pavlakis, Nick
Wolleb, Sibylle
Petrausch, Ulf
O'Byrne, Kenneth
Froesch, Patrizia
Loffler-Baumann, Melanie
Pratsch-Peter, Susanne
Russell, Prudence
Mingrone, Walter
Savic, Spasenija
Thapa, Bibhusal
Fruh, Martin
Pless, Miklos
von Moos, Roger
John, Thomas
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1784 - 1791
[32] An appropriate choice for immunotherapy in malignant pleural mesothelioma
Fujimoto, Nobukazu
EBIOMEDICINE, 2020, 62
[33] The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, Daniel R.
Kamath, Suneel D.
Korc, Murray
Munshi, Hidayatullah G.
PHARMACOLOGY & THERAPEUTICS, 2022, 236
[34] The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma
Nirosha D. Perera
Aaron S. Mansfield
Current Oncology Reports, 2022, 24 : 1413 - 1423
[35] The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma
Perera, Nirosha D.
Mansfield, Aaron S.
CURRENT ONCOLOGY REPORTS, 2022, 24 (11) : 1413 - 1423
[36] Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors
Chang, Meng Rui
Matnurov, Egor M.
Wu, Chengnan
Arakelyan, Jemma
Choe, Ho-Jung
Kushnarev, Vladimir
Yap, Jian Yu
Soo, Xiu Xuan
Chow, Mun Juinn
Berger, Walter
Ang, Wee Han
Babak, Maria V.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2025, 147 (09) : 7908 - 7920
[37] A topical chemo-immunotherapy for squamous cell carcinoma
Friedman, Blake
Donahue, Cara
Erdos, Geza
Falo, Louis D.
JOURNAL OF IMMUNOLOGY, 2016, 196
[38] Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers
Creaney, Jenette
Dick, Ian M.
Musk, A. W.
Olsen, Nola J.
Robinson, Bruce W. S.
BIOMARKERS, 2016, 21 (06) : 551 - 561
[39] ADJUVANT CHEMO-IMMUNOTHERAPY FOR STAGE IIIB MALIGNANT-MELANOMA
ABDI, EA
KAMITOMO, VJ
HANSON, J
MCPHERSON, TA
MEDICAL AND PEDIATRIC ONCOLOGY, 1985, 13 (03): : 156 - 156
[40] Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy
Nowak, AK
Robinson, BWS
Lake, RA
CANCER RESEARCH, 2002, 62 (08) : 2353 - 2358

← 1 2 3 4 5 →